The present invention provides an Actinidia chinensis Planch ferment and the use thereof in a composition for increasing the antioxidant activity, increasing the anti-glycation activity, increasing the activity of proteolytic enzymes, improving the gastrointestinal dyspepsia, and increasing the gastrointestinal flora diversity. The Actinidia chinensis Planch ferment is prepared by fermenting Actinidia chinensis Planch extract with yeast, lactic acid bacteria and acetic acid bacteria in a three-staged fermentation.

Disclosed herein are compositions containing a modified starch, the starch modified to contain ester linkages to multiple short-chain fatty acids of different lengths; in particular, containing linkages to acetate, propionate, and butyrate. Methods for making and using such starch esters are described, as are compositions including the starch ester for nutritional effects and health benefits.

Disclosed herein are compositions containing a modified starch, the starch modified to contain ester linkages to multiple short-chain fatty acids of different lengths; in particular, containing linkages to acetate, propionate, and butyrate. Methods for making and using such starch esters are described, as are compositions including the starch ester for nutritional effects and health benefits.

The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, etc. are defined as in claim 1.

The present invention relates to a liquid composition for enriching aqueous or hydro-alcoholic food, cosmetic and/or dermatological products. The invention also relates to the use of said liquid composition and to the method for producing said liquid composition.

The present invention relates to a liquid composition for enriching aqueous or hydro-alcoholic food, cosmetic and/or dermatological products. The invention also relates to the use of said liquid composition and to the method for producing said liquid composition.

The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.